Interview with Dr Sven Kili from GlaxoSmithKline

We had the pleasure of talking with Dr Sven Kili, VP and Head of Cell & Gene Therapy Development at GlaxoSmithKline about the next steps now that Strimvelis has been approved, the changing model of orphan drug designation, and how the commercial supply chain strategy for Strimvelis is taking shape.

Interview with Dr Sven Kili from GlaxoSmithKline